A previous case–control study conducted in our center has shown 4.0% of metachronous contralateral breast cancer recurrence in BRCA1/2-negative patients with risk factors for hereditary breast and/or ovarian cancer31. This evidence concerns the gene BRCA1 and breast cancer.